Functional genomics identified a novel protein tyrosine phosphatase receptor type f‐mediated growth inhibition in hepatocarcinogenesis

It is unclear how proliferating cells elicit suppression on cell proliferation and how cancer cells evade this growth suppression. Using a loss‐of‐function screening of the human kinome and phosphatome to identify genes suppressing tumor initiation in human hepatocellular carcinoma (HCC), we identified 19 genes and characterized one of the top‐scoring tumor suppressor candidates, protein tyrosine phosphatase receptor type F (PTPRF). We found that PTPRF was induced during cell proliferation by cell‐cell contact. Ectopic expression of wild‐type PTPRF, but not the phosphatase‐inactive mutant, suppressed cell proliferation and colony formation in soft‐agar assays. In contrast, PTPRF silencing led to cell hyperproliferation, enhanced tumor colony formation in soft agar, and increased xenograft tumor growth in nude mice. Mechanistically, PTPRF silencing showed aberrant ERK‐dependent signaling including the phosphorylation/stabilization of v‐myc avian myelocytomatosis viral oncogene homolog (MYC) through the direct activation of v‐src avian sarcoma viral oncogene homolog (SRC) and suppression of PP2A. This PTPRF‐mediated growth suppression during cell proliferation functioned independently of the Hippo‐Yap pathway. Clinically, PTPRF was down‐regulated in 42% HCC (37/89), 67% gastric cancer (27/40), and 100% colorectal cancer (40/40). PTPRF up‐regulation was found in 24% HCC (21/89) and associated with better clinical outcomes. Conclusion: A novel PTPRF‐mediated growth suppression pathway was identified by way of a functional genomics screening in human hepatoma cells. Induction of PTPRF by cell‐cell contact during cell proliferation quenched the activated ERK‐dependent proliferation signaling to prevent cell hyperproliferation and tumor initiation. PTPRF down‐regulation in HCC facilitated tumor development. Our findings shed light on how cancer cells can evade growth suppression and open a new avenue for future development of anticancer therapies. (Hepatology 2014;59:2238–2250)

[1]  A. Davis,et al.  Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Toshikazu Nakamura,et al.  Contact Inhibition of Hepatocyte Growth Regulated by Functional Association of the c-Met/Hepatocyte Growth Factor Receptor and LAR Protein-tyrosine Phosphatase* , 2006, Journal of Biological Chemistry.

[3]  T. Hunter,et al.  Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling , 1995, Cell.

[4]  W. Miller,et al.  SRC points the way to biomarkers and chemotherapeutic targets. , 2012, Genes & cancer.

[5]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[6]  F. Camargo,et al.  The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and development. , 2013, Current opinion in cell biology.

[7]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[8]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[9]  J. Nevins,et al.  Ras enhances Myc protein stability. , 1999, Molecular cell.

[10]  R. Bernabeu,et al.  Downregulation of the LAR protein tyrosine phosphatase receptor is associated with increased dentate gyrus neurogenesis and an increased number of granule cell layer neurons , 2006, Molecular and Cellular Neuroscience.

[11]  E. Haura,et al.  Src kinases as therapeutic targets for cancer , 2009, Nature Reviews Clinical Oncology.

[12]  R. Metcalf,et al.  p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. , 1993, Carcinogenesis.

[13]  Qiang Yu,et al.  Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines , 2004, Molecular and Cellular Biochemistry.

[14]  O. Kirak,et al.  Yap1 Acts Downstream of α-Catenin to Control Epidermal Proliferation , 2011, Cell.

[15]  W. Weng,et al.  Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma , 2011, Hepatology.

[16]  N. Hay,et al.  Akt-phosphorylated Mitogen-activated Kinase-activating Death Domain Protein (MADD) Inhibits TRAIL-induced Apoptosis by Blocking Fas-associated Death Domain (FADD) Association with Death Receptor 4* , 2010, The Journal of Biological Chemistry.

[17]  L. Vermeulen.  Keeping stem cells in check: a hippo balancing act. , 2013, Cell stem cell.

[18]  N. Nomura,et al.  Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin- mediated cell-cell adhesion. , 1998, Science.

[19]  J. Nault,et al.  Molecular Classification of Hepatocellular Adenomas , 2013, International journal of hepatology.

[20]  D. Pan,et al.  The hippo signaling pathway in development and cancer. , 2010, Developmental cell.

[21]  M. Runge,et al.  Leukocyte Antigen-related Deficiency Enhances Insulin-like Growth Factor-1 Signaling in Vascular Smooth Muscle Cells and Promotes Neointima Formation in Response to Vascular Injury* , 2007, Journal of Biological Chemistry.

[22]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers , 2004, Science.

[23]  S. Hsieh,et al.  A novel interaction of nucleophosmin with BCL2‐associated X protein regulating death evasion and drug sensitivity in human hepatoma cells , 2013, Hepatology.

[24]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[25]  Bin Zhao,et al.  The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal , 2011, Nature Cell Biology.

[26]  S. Hardy,et al.  Inside the human cancer tyrosine phosphatome , 2010, Nature Reviews Cancer.

[27]  N. Tapon,et al.  Combined functional genomic and proteomic approaches identify a PP2A complex as a negative regulator of Hippo signaling. , 2010, Molecular cell.

[28]  K. Guan,et al.  Organ Size Control by Hippo and TOR Pathways , 2012, Current Biology.

[29]  Hidenori Ojima,et al.  High-resolution characterization of a hepatocellular carcinoma genome , 2011, Nature Genetics.

[30]  F. Da Settimo,et al.  Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview. , 2011, Current medicinal chemistry.

[31]  C. Hodgkinson,et al.  Knock‐down of LAR protein tyrosine phosphatase induces insulin resistance , 2005, FEBS letters.

[32]  L. Neckers,et al.  Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. , 2001, Cancer research.

[33]  B. Rothen‐Rutishauser,et al.  Dynamics of Tight and Adherens Junctions Under EGTA Treatment , 2002, The Journal of Membrane Biology.

[34]  Nir Hacohen,et al.  Genome-scale loss-of-function screening with a lentiviral RNAi library , 2006, Nature Methods.

[35]  Eunjoon Kim,et al.  Slitrks control excitatory and inhibitory synapse formation with LAR receptor protein tyrosine phosphatases , 2013, Proceedings of the National Academy of Sciences.

[36]  B. Goldstein,et al.  Insulin Receptor Signaling Is Augmented by Antisense Inhibition of the Protein Tyrosine Phosphatase LAR (*) , 1995, The Journal of Biological Chemistry.

[37]  C. LeVea,et al.  Expression of the leucocyte common antigen-related (LAR) tyrosine phosphatase is regulated by cell density through functional E-cadherin complexes. , 2002, The Biochemical journal.

[38]  E. Raymond,et al.  [Targeted therapies in hepatocellular carcinoma]. , 2010, Presse medicale.

[39]  J. Bruix,et al.  Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects , 2010, Seminars in liver disease.

[40]  M. Sherman.  Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. , 2010, Seminars in liver disease.

[41]  C C Howe,et al.  Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. , 1980, Science.

[42]  K. Harvey,et al.  The Hippo Size Control Pathway—Ever Expanding , 2013, Science Signaling.

[43]  W. Hahn,et al.  Multiple pathways regulated by the tumor suppressor PP2A in transformation. , 2008, Trends in molecular medicine.